

Literatur

- Katon, W.J., Epidemiology and treatment of depression in patients with chronic medical illness. *Dialogues in clinical neuroscience*, 2011. 13(1): 7-23.
- Hackett, M.L. and K. Pickles, Part I: Frequency of Depression after Stroke: An Updated Systematic Review and Meta-Analysis of Observational Studies. *International Journal of Stroke*, 2014. 9(8): 1017-1025.
- Rotella, F. and E. Mannucci, Depression as a risk factor for diabetes: a meta-analysis of longitudinal studies. *J Clin Psychiatry*, 2013. 74(1): 31-7.
- Nicholson, A., H. Kuper, and H. Hemingway, Depression as an aetiologic and prognostic factor in coronary heart disease: a meta-analysis of 6362 events among 146 538 participants in 54 observational studies. *Eur Heart J*, 2006. 27(23): 2763-74.
- Pan, A., et al., Depression and Risk of Stroke Morbidity and Mortality: A Meta-analysis and Systematic Review. *JAMA*, 2011. 306(11): 1241-1249.
- Rotella, F. and E. Mannucci, Diabetes mellitus as a risk factor for depression. A meta-analysis of longitudinal studies. *Diabetes Res Clin Pract*, 2013. 99(2): 98-104.
- Wium-Andersen, M.K., et al., An attempt to explain the bidirectional association between ischaemic heart disease, stroke and depression: a cohort and meta-analytic approach. *Br J Psychiatry*, 2019: 1-8.
- Penninx, B. and S.M.M. Lange, Metabolic syndrome in psychiatric patients: overview, mechanisms, and implications. *Dialogues Clin Neurosci*, 2018. 20(1): 63-73.
- Razmara, A., et al., Depression Is Associated with a Higher Risk of Death among Stroke Survivors. *J Stroke Cerebrovasc Dis*, 2017. 26(12): 2870-2879.
- Scherrer, J.F., et al., Treatment-resistant and insufficiently treated depression and all-cause mortality following myocardial infarction. *Br J Psychiatry*, 2012. 200(2): 137-42.
- Woo, Y.S., et al., Association of treatment response with obesity and other metabolic risk factors in adults with depressive disorders: Results from a National Depression Cohort study in Korea (the CRESCEND study). *J Affect Disord*, 2016. 203: 190-198.
- Mulvahill, J.S., et al., Effect of Metabolic Syndrome on Late-Life Depression: Associations with Disease Severity and Treatment Resistance. *J Am Geriatr Soc*, 2017. 65(12): 2651-2658.
- Vogelzangs, N., et al., Inflammatory and metabolic dysregulation and the 2-year course of depressive disorders in antidepressant users. *Neuropsychopharmacology*: official publication of the American College of Neuropsychopharmacology, 2014. 39(7): 1624-34.
- Sagud, M., et al., The lack of association between components of metabolic syndrome and treatment resistance in depression. *Psychopharmacology (Berl)*, 2013. 230(1): 15-21.
- Fostick, L., et al., The economic impact of depression: resistance or severity? *Eur Neuropsychopharmacol*, 2010. 20(10): 671-5.
- Reutfors, J., et al., Mortality in treatment-resistant unipolar depression: A register-based cohort study in Sweden. *J Affect Disord*, 2018. 238: 674-679.
- Gilsanz, J., et al., Changes in Depressive Symptoms and Subsequent Risk of Stroke in the Cardiovascular Health Study. *Stroke*, 2017. 48(1): 43-48.
- Serretti, A. and L. Mandelli, Antidepressants and body weight: a comprehensive review and meta-analysis. *J Clin Psychiatry*, 2010. 71(10): 1259-72.
- DGPPN, BÄK, KBV, AWMF (Hrsg.) für die Leitliniengruppe Unipolare Depression., S3-Leitlinie/Nationale VersorgungsLeitlinie Unipolare Depression – Langfassung, 2. Auflage. Version 5. 2015; Available from: www.depression.versorgungsleitlinien.de.
- Anderson, R.J., et al., The prevalence of comorbid depression in adults with diabetes: a meta-analysis. *Diabetes Care*, 2001. 24(6): 1069-78.
- Vancampfort, D., et al., TYPE 2 DIABETES IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER: A META-ANALYSIS OF PREVALENCE ESTIMATES AND PREDICTORS. *Depress Anxiety*, 2015. 32(10): 763-73.
- de Groot, M., et al., Association of depression and diabetes complications: a meta-analysis. *Psychosom Med*, 2001. 63(4): 619-30.
- Baumeister, H., N. Hutter, and J. Bengel, Psychological and pharmacological interventions for depression in patients with diabetes mellitus: an abridged Cochrane review. *Diabet Med*, 2014. 31(7): 773-86.
- Roopan, S. and E.R. Larsen, Use of antidepressants in patients with depression and comorbid diabetes mellitus: a systematic review. *Acta Neuropsychiatr*, 2017. 29(3): 127-139.
- Petrak, F., et al., Cognitive Behavioral Therapy Versus Sertraline in Patients With Depression and Poorly Controlled Diabetes: The Diabetes and Depression (DAD) Study: A Randomized Controlled Multicenter Trial. *Diabetes Care*, 2015. 38(5): 767-75.
- Lustman, J., et al., Depression and poor glycemic control: a meta-analytic review of the literature. *Diabetes Care*, 2000. 23(7): 934-42.
- Stolar, M., Glycemic control and complications in type 2 diabetes mellitus. *Am J Med*, 2010. 123(3 Suppl): S3-11.
- Goodnick, J., et al., Sertraline in coexisting major depression and diabetes mellitus. *Psychopharmacol Bull*, 1997. 33(2): 261-4.
- Salvi, V., et al., The risk of new-onset diabetes in antidepressant users - A systematic review and meta-analysis. *PLoS One*, 2017. 12(7): e0182088.
- Derijks, H.J., et al., The association between antidepressant use and disturbances in glucose homeostasis: evidence from spontaneous reports. *European Journal of Clinical Pharmacology*, 2008. 64(5): 531-538.
- Boulton, A.J., et al., Diabetic neuropathies: a statement by the American Diabetes Association. *Diabetes Care*, 2005. 28(4): 956-62.
- Cording, M., et al., Milnacipran for pain in fibromyalgia in adults. *Cochrane Database Syst Rev*, 2015(10): CD008244.
- Rowbotham, M.C., et al., Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. *Pain*, 2004. 110(3): 697-706.
- Benkert, O. and H. Hippus, *Kompendium der Psychiatrischen Pharmakotherapie*. 12., vollständig überarbeitete und aktualisierte Auflage. ed. 2019, Berlin, Heidelberg: Berlin, Heidelberg: Springer Berlin Heidelberg: Imprint: Springer. 1 online resource (1,081 pages).
- Kang, R., et al., Comparison of paroxetine and agomelatine in depressed type 2 diabetes mellitus patients: a double-blind, randomized, clinical trial. *Neuropsychiatr Dis Treat*, 2015. 11: 1307-11.
- Lustman, J., et al., Factors influencing glycemic control in type 2 diabetes during acute- and maintenance-phase treatment of major depressive disorder with bupropion. *Diabetes Care*, 2007. 30(3): 459-66.
- Abrahamian, H., et al., Diabetes mellitus and comorbid depression: improvement of both diseases with milnacipran. A replication study (results of the Austrian Major Depression Diabetes Mellitus study group). *Neuropsychiatr Dis Treat*, 2012. 8: 355-60.
- Boles, A., R. Kandimalla, and H. Reddy, Dynamics of diabetes and obesity: Epidemiological perspective. *Biochim Biophys Acta Mol Basis Dis*, 2017. 1863(5): 1026-1036.
- Luppino, F.S., et al., Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. *Arch Gen Psychiatry*, 2010. 67(3): 220-9.
- Salvi, V., C. Mencacci, and F. Barone-Adesi, H1-histamine receptor affinity predicts weight gain with antidepressants. *Eur Neuropsychopharmacol*, 2016. 26(10): 1673-7.
- Lee, S.H., et al., Is increased antidepressant exposure a contributory factor to the obesity pandemic? *Translational psychiatry*, 2016. 6(3): e759-e759.
- Arnold, L.M., et al., Effect of milnacipran on body weight in patients with fibromyalgia. *Int J Gen Med*, 2012. 5: 879-87.
- Otte, C., Einfluss von Depression und Antidepressiva auf Adipositas, metabolisches Syndrom und Diabetes mellitus Typ 2. *Psychopharmakotherapie*, 2017. 24.
- Institute for Health Metrics and Evaluation (IHME), Findings from the Global Burden of Disease Study 2017. 2018, Seattle, WA: IHME.
- Carney, R.M. and K.E. Freedland, Depression in patients with coronary heart disease. *Am J Med*, 2008. 121(11 Suppl 2): S20-7.
- Rumsfeld, J.S., et al., Depression predicts mortality and hospitalization in patients with myocardial infarction complicated by heart failure. *Am Heart J*, 2005. 150(5): 961-7.
- Ostuzzi, G., et al., Efficacy and acceptability of antidepressants in patients with ischemic heart disease: systematic review and meta-analysis. *Int Clin Psychopharmacol*, 2019. 34(2): 65-75.
- Glassman, A.H., et al., Sertraline treatment of major depression in patients with acute MI or unstable angina. *Jama*, 2002. 288(6): 701-9.
- Lesperance, F., et al., Effects of citalopram and interpersonal psychotherapy on de-

- pression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial. *Jama*, 2007. 297(4): 367-79.
50. Glassman, A.H., J.T. Bigger, Jr., and M. Gaffney, Psychiatric characteristics associated with long-term mortality among 361 patients having an acute coronary syndrome and major depression: seven-year follow-up of SADHART participants. *Arch Gen Psychiatry*, 2009. 66(9): 1022-9.
 51. Carney, R.M., et al., Depression and late mortality after myocardial infarction in the Enhancing Recovery in Coronary Heart Disease (ENRICH) study. *Psychosom Med*, 2004. 66(4): 466-74.
 52. Kim, J.M., et al., Effect of Escitalopram vs Placebo Treatment for Depression on Long-term Cardiac Outcomes in Patients With Acute Coronary Syndrome: A Randomized Clinical Trial. *Jama*, 2018. 320(4): 350-358.
 53. Lavoie, K.L., et al., Relationship between antidepressant therapy and risk for cardiovascular events in patients with and without cardiovascular disease. *Health Psychol*, 2018. 37(11): 989-999.
 54. Zuidersma, M., et al., Depression treatment after myocardial infarction and long-term risk of subsequent cardiovascular events and mortality: a randomized controlled trial. *J Psychosom Res*, 2013. 74(1): 25-30.
 55. Almeida, O., et al., Depression, antidepressant use and mortality in later life: the Health In Men Study. *PLoS One*, 2010. 5(6): e11266.
 56. Smoller, J.W., et al., Antidepressant use and risk of incident cardiovascular morbidity and mortality among postmenopausal women in the Women's Health Initiative study. *Arch Intern Med*, 2009. 169(22): 2128-39.
 57. Coupland, C., et al., Antidepressant use and risk of adverse outcomes in older people: population based cohort study. *Bmj*, 2011. 343: d4551.
 58. Hansen, R.A., et al., Antidepressant Medication Use and Its Association With Cardiovascular Disease and All-Cause Mortality in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. *The Annals of pharmacotherapy*, 2016. 50(4): 253-261.
 59. O'Connor, C.M., et al., Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial. *J Am Coll Cardiol*, 2010. 56(9): 692-9.
 60. Jiang, W., et al., Characteristics of depression remission and its relation with cardiovascular outcome among patients with chronic heart failure (from the SADHART-CHF Study). *Am J Cardiol*, 2011. 107(4): 545-51.
 61. Angermann, C.E., et al., Effect of Escitalopram on All-Cause Mortality and Hospitalization in Patients With Heart Failure and Depression: The MOOD-HF Randomized Clinical Trial. *JAMA*, 2016. 315(24): 2683-93.
 62. Rajeswaran, T., C.M. Plymen, and A.M. Doherty, The effect of antidepressant medications in the management of heart failure on outcomes: mortality, cardiovascular function and depression - a systematic review. *Int J Psychiatry Clin Pract*, 2018. 22(3): 164-169.
 63. Beach, S.R., et al., Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation. *J Clin Psychiatry*, 2014. 75(5): e441-9.
 64. Albus, C., K.H. Ladwig, and C. Herrmann-Lingen, [Psychocardiology: clinically relevant recommendations regarding selected cardiovascular diseases]. *Dtsch Med Wochenschr*, 2014. 139(12): 596-601.
 65. Ayerbe, L., et al., Natural history, predictors and outcomes of depression after stroke: systematic review and meta-analysis. *British Journal of Psychiatry*, 2013. 202(1): 14-21.
 66. Xu, X.M., et al., Efficacy and feasibility of antidepressant treatment in patients with post-stroke depression. *Medicine (Baltimore)*, 2016. 95(45): e5349.
 67. Choi-Kwon, S., et al., Fluoxetine treatment in poststroke depression, emotional incontinence, and anger proneness: a double-blind, placebo-controlled study. *Stroke*, 2006. 37(1): 156-61.
 68. Murray, V., et al., Double-blind comparison of sertraline and placebo in stroke patients with minor depression and less severe major depression. *J Clin Psychiatry*, 2005. 66(6): 708-16.
 69. Fruehwald, S., et al., Early fluoxetine treatment of post-stroke depression--a three-month double-blind placebo-controlled study with an open-label long-term follow up. *J Neurol*, 2003. 250(3): 347-51.
 70. Spalletta, G. and C. Caltagirone, Sertraline treatment of post-stroke major depression: an open study in patients with moderate to severe symptoms. *Funct Neurol*, 2003. 18(4): 227-32.
 71. Gao, J., et al., Different interventions for post-ischaemic stroke depression in different time periods: a single-blind randomized controlled trial with stratification by time after stroke. *Clin Rehabil*, 2017. 31(1): 71-81.
 72. Tan, S., et al., Efficacy and Safety of Citalopram in Treating Post-Stroke Depression: A Meta-Analysis. *Eur Neurol*, 2015. 74(3-4): 188-201.
 73. Bhogal, S.K., et al., Heterocyclics and selective serotonin reuptake inhibitors in the treatment and prevention of poststroke depression. *J Am Geriatr Soc*, 2005. 53(6): 1051-7.
 74. Jorge, R.E., et al., Mortality and poststroke depression: a placebo-controlled trial of antidepressants. *Am J Psychiatry*, 2003. 160(10): 1823-9.
 75. Laporte, S., et al., Bleeding risk under selective serotonin reuptake inhibitor (SSRI) antidepressants: A meta-analysis of observational studies. *Pharmacol Res*, 2017. 118: 19-32.
 76. Mortensen, J.K., et al., Post stroke use of selective serotonin reuptake inhibitors and clinical outcome among patients with ischemic stroke: a nationwide propensity score-matched follow-up study. *Stroke*, 2013. 44(2): 420-6.
 77. Shin, D., et al., Use of selective serotonin reuptake inhibitors and risk of stroke: a systematic review and meta-analysis. *J Neurol*, 2014. 261(4): 686-95.
 78. Jensen, M., et al., The impact of selective serotonin reuptake inhibitors on the risk of intracranial haemorrhage: A systematic review and meta-analysis. *Eur Stroke J*, 2019. 4(2): 144-152.
 79. Hackam, D.G. and M. Mrkobrada, Selective serotonin reuptake inhibitors and brain hemorrhage: a meta-analysis. *Neurology*, 2012. 79(18): 1862-5.
 80. Anglin, R., et al., Risk of upper gastrointestinal bleeding with selective serotonin reuptake inhibitors with or without concurrent nonsteroidal anti-inflammatory use: a systematic review and meta-analysis. *Am J Gastroenterol*, 2014. 109(6): 811-9.
 81. Andrade, C., et al., Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. *J Clin Psychiatry*, 2010. 71(12): 1565-75.
 82. Niedermaier, N., et al., Prevention and treatment of poststroke depression with mirtazapine in patients with acute stroke. *J Clin Psychiatry*, 2004. 65(12): 1619-23.
 83. Aragona, B., et al., Is bupropion useful in the treatment of post-stroke thalamic apathy? A case report and considerations. *Funct Neurol*, 2018. 33(4): 213-216.
 84. Paolucci, S., Advances in antidepressants for treating post-stroke depression. *Expert Opin Pharmacother*, 2017. 18(10): 1011-1017.
 85. Salter, K.L., et al., Prevention of poststroke depression: does prophylactic pharmacotherapy work? *J Stroke Cerebrovasc Dis*, 2013. 22(8): 1243-51.
 86. Kim, J.S., et al., Efficacy of early administration of escitalopram on depressive and emotional symptoms and neurological dysfunction after stroke: a multicentre, double-blind, randomised, placebo-controlled study. *Lancet Psychiatry*, 2017. 4(1): 33-41.
 87. Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial. *Lancet*, 2019. 393(10168): 265-274.
 88. Hackett, M.L., C.S. Anderson, and A.O. House, Management of depression after stroke: a systematic review of pharmacological therapies. *Stroke*, 2005. 36(5): 1098-103.
 89. Hackett, M.L., et al., Interventions for treating depression after stroke. *Cochrane Database Syst Rev*, 2008(4): Cd003437.
 90. Sun, Y., et al., Comparative efficacy and acceptability of antidepressant treatment in poststroke depression: a multiple-treatments meta-analysis. *BMJ Open*, 2017. 7(8): e016499.
 91. Deng, L., et al., Efficacy and tolerability of pharmacotherapy for post-stroke depression: a network meta-analysis. *Oncotarget*, 2018. 9(34): 23718-23728.